393 related articles for article (PubMed ID: 34263961)
1. Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.
Infante M; Baidal DA; Rickels MR; Fabbri A; Skyler JS; Alejandro R; Ricordi C
Artif Organs; 2021 Sep; 45(9):968-986. PubMed ID: 34263961
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
3. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
Haidar A; Tsoukas MA; Bernier-Twardy S; Yale JF; Rutkowski J; Bossy A; Pytka E; El Fathi A; Strauss N; Legault L
Diabetes Care; 2020 Mar; 43(3):597-606. PubMed ID: 31974099
[TBL] [Abstract][Full Text] [Related]
4. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
5. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
[TBL] [Abstract][Full Text] [Related]
6. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.
Majdpour D; Tsoukas MA; Yale JF; El Fathi A; Rutkowski J; Rene J; Garfield N; Legault L; Haidar A
Can J Diabetes; 2021 Dec; 45(8):734-742. PubMed ID: 33888413
[TBL] [Abstract][Full Text] [Related]
7. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
[TBL] [Abstract][Full Text] [Related]
8. Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.
Abitbol A; Rabasa-Lhoret R; Messier V; Legault L; Smaoui M; Cohen N; Haidar A
Diabetes Technol Ther; 2018 Mar; 20(3):189-196. PubMed ID: 29393675
[TBL] [Abstract][Full Text] [Related]
9. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
[TBL] [Abstract][Full Text] [Related]
10. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.
Haidar A; Rabasa-Lhoret R; Legault L; Lovblom LE; Rakheja R; Messier V; D'Aoust É; Falappa CM; Justice T; Orszag A; Tschirhart H; Dallaire M; Ladouceur M; Perkins BA
J Clin Endocrinol Metab; 2016 Jan; 101(1):214-23. PubMed ID: 26523526
[TBL] [Abstract][Full Text] [Related]
11. Closing the Loop on Exercise in Type 1 Diabetes.
Bally L; Thabit H
Curr Diabetes Rev; 2018; 14(3):257-265. PubMed ID: 28245784
[TBL] [Abstract][Full Text] [Related]
12. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
13. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
[TBL] [Abstract][Full Text] [Related]
14. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
[TBL] [Abstract][Full Text] [Related]
16. Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system.
Hanazaki K; Munekage M; Kitagawa H; Yatabe T; Munekage E; Shiga M; Maeda H; Namikawa T
J Artif Organs; 2016 Sep; 19(3):209-18. PubMed ID: 27142278
[TBL] [Abstract][Full Text] [Related]
17. Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.
Taleb N; Haidar A; Messier V; Gingras V; Legault L; Rabasa-Lhoret R
Diabetes Obes Metab; 2017 Jan; 19(1):13-23. PubMed ID: 27629286
[TBL] [Abstract][Full Text] [Related]
18. Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems.
Peters TM; Haidar A
Diabet Med; 2018 Apr; 35(4):450-459. PubMed ID: 29337384
[TBL] [Abstract][Full Text] [Related]
19. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
[TBL] [Abstract][Full Text] [Related]
20. Role of Glucagon in Automated Insulin Delivery.
Wilson LM; Jacobs PG; Castle JR
Endocrinol Metab Clin North Am; 2020 Mar; 49(1):179-202. PubMed ID: 31980117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
